Table 5.
Seroprevalence of T. gondii antibodies in patients with several disorders
| Population | Age range | Governorate | No. tested | No. positive (%) | Test | IgM | Reference |
|---|---|---|---|---|---|---|---|
| Meningoencephalitis | NS | Cairo | 42a | 10 (26.0) | IFA | ND | Mabrouk and Dahawi (1991) |
| Cryptogenic epilepsy | 2–46 yr | Zagazig | 72 | 25 (34.7) | ELISA-IgG11 | ND | Abd El-Aal et al. (2016) |
| Non-cryptogenic epilepsy | 40 | 1 (2.5) | |||||
| Depression | 118 | 24 (20.3) | |||||
| Cryptogenic epilepsy | 9 mo-18 yr | Kalubiya | 40 | 8 (20.0) | ELISA-IgG11 | ND | Eraky et al. (2016) |
| Non-cryptogenic epilepsy | 30 | None | |||||
| Schizophrenia | 20–60 yr | Damietta | 100 | 47 (47.0) | ELISA-IgG22 | ND | Saad et al. (2016) |
| Non-schizophrenic neurodevelopmental disorders | < or >20 yr | Alexandria | 188 | 94 (50.0) | ELISA-IgG8 | 31 (16.5) | Shehata et al. (2016) |
| Neurological disorders without chromosomal anomalies | ⩽5 yr | Dakahlia | 30 | 19 (63.3) | ELISA-IgG8 | 11 (36.7) | El-Beshbishi et al. (2018) |
| Down syndrome | 30 | 4 (13.3) | 1 (3.3) | ||||
| Mental retardation | 2 mo-12 yr | Cairo | 200 | 84 (42.0) | IHA1 | ND | Hamed et al. (2018) |
| Chronic liver disease | 50–60 yr | Dakahlia | 120 | 105 (87.5) | ELISA-IgG25 | 16 (13.3) | El-Nahas et al. (2014) |
| Controls | 40 | 6 (15.0) | 3 (7.5) | ||||
| Chronic liver disease | 19–66 yr | Cairo | 70 | 21 (30.0) | PCR-blood | ND | El-Sayed et al. (2016b) |
| Controls | 50 | 3 (6.0) | |||||
| Tonsilitis | 4–20 yr | Zagazig | 100 | 55 (55.0) | IFAT | ND | El-Ridi et al. (1989) |
| Controls | 50 | 12 (24.0) |
ND, not done; NS, not stated; mo, month; yr, year.
a
Pathogenic bacteria were excluded.